BrightOwl Loader Loading

Summary

mark is Director, science Policy in the global Policy & corporate responsibility team based in luton, uk. 6 y science Policy experience at astrazeneca mostly in R&D but for past year in corporate affairs. as chair of the astrazeneca bioethics advisory group, responsible for evolving astrazeneca global bioethics Policy including Clinical trials transparency and quality; access to human tissue for use in Research; big data and data privacy; human Stem Cells; precise genome Editing; synthetic Biology. background: educated at southampton University, uk and University of chicago, mark is a phd pharmacologist/physiologist (>50 peer-reviewed Publications – most recently on public attitudes to human Biological sample donation for Research, bmj open 2014). 30 y pharma experience mostly on drug project delivery (7 years as section manager of astra pre-clinical team that conceived the principle of and discovered the anti-thrombotic agents brilinta and cangrelor) and methods to improve R&D productivity. worked in several pharma (including 10 y at gsk), disease areas and business models. astra/zeneca merger team Member. current interest areas: science Policy; bioethics; responsible business and corporate sustainability; precise genome Editing/Gene therapy Ethics; biodiversity/nagoya science)" >Protocol; personalised Healthcare (and connection to value demonstration and price); Clinical Trial transparency, donor and patient consent/ data privacy, access to human Biological samples including Stem Cells and other fetal tissue; synthetic Biology. network: connected extensively across global astrazeneca plus international external connections to other pharma. academia, nhs and uk/ european/global government organisations, trade associations and ngos.

Experiences

Current Experience

  • Director, Science Policy, Global Policy & Corporate Responsibility, Corporate Affairs


    Since December 2013

Past Experience

  • Science Policy Strategy Lead

    March 2011 --- January 2014
    horizon scanning trends in biomedicine Ethics across a broad range of topics and anticipating potential impact in R&D. working with senior stakeholders inside and outside az to agree new Policy and guidelines for az scientists.

  • R&D Science Policy Director

    October 2009 --- April 2011
    R&D bioethics at az and liaison to other phama and uk academia & government/ agencies. current interests: neglected diseases; pre-competitive data sharing; Stem Cells & regenerative Medicine; Clinical trials Ethics

  • Strategy & Portfolio Director, New Opportunities

    August 2007 --- August 2009
    repurposing existing az Biological targets and compounds to new opportunities for az currently outside the az disease area Strategy portfolio

  • Director, Discovery Strategy Portfolio and Performance

    July 2001 --- July 2007
    support for az Discovery Leadership team

  • R&D Integration Office

    March 2000 --- June 2001
    part of a small team that organised the integration of astra and zeneca r&d

  • Discovery Section Manager

    October 1992 --- August 1999
    astra (fisons 1 year): drug project Scientist, leader and manager. at various times over 7 years: early development Project Leader; section manager (~30 staff); dx Project Leader; team leader in drug project teams. two compounds from this work are currently in Phase III (both cardiovascular). one is brillinta - a novel p2y12 receptor antagonist

  • Team Leader and bench scientist

    June 1982 --- September 1992
    after my 2 y post-doc at univeristy of chicago i worked at glaxo/glaxowellcome for 10 y. mostly cv are especially smooth muscle Physiology and pharmacology In Vitro and In Vivo. voltage-gated calcium channels, alpha receptors, angiotensin receptor antagonists. we nominated an at1 receptor antagonist for man.

Personality

Self Assessment :
AdaptabilityCreative thinkingCuriosityDependabilityInnovative thinkingResult Oriented

Knowledge

Self Assessment :
R&D Scientific writingBiomedical SciencesBusiness IntelligenceCardiovascular diseasesDrug DiscoveryInformed Consent ProcessMergers & AcquisitionsPhysiologypharmacologyPharmaceutical ResearchScientific WritingRisk ManagementStem cell researchIn VivoAnimal Health
LinkedIn Assessment :
pharmacologyBioethicsscience policyClinical trialsHuman tissue use in researchResponsible BusinessTropical MedicineDeveloping World suppotResearchPharmaceutical IndustryTropical MedicineDrug DevelopmentDrug DiscoveryLifesciencesIn VitroStrategyBiomarkersClinical DevelopmentBiopharmaceuticalsLife SciencesBiotechnologyoncology

Skills and Expertise

Self Assessment :
Receptor Pharmacology Write papersCollaborate with project teamCommunicate effectively on different company levelsCoachDesign scientific projects (in biology)Design subject consent formEstablish professional relationships with partnersEthics committee submissionsGuide staffIdentify risksInformed consent processInteract with pre-clinical scientistsManage risksRead medical literature to maintain current awareness and knowledgeResolves queriesReview informed consent processWrite documents

Education

  • Post-doc in Clinical pharmacology from University of Chicago - The Pritzker School of Medicine in 1982
  • BSc, PhD in Physiology & Biochemistry; Pharmacology from University of Southampton in 1980

Work Preferences

  • Notice Period:
    12 weeks
  • Positions I am interested in:
    Scientific consultant Scientific Writer
  • Work From Home:
    Yes, 0 to 2 days per week
  • Work Regime:
    BrightOwl freelancer
  • International:
    No

Area / Region

United Kingdom

Others

Driving License
  • Yes

Similar Candidates

Other Candidates in United Kingdom

Other similar Candidates in this location (country / city)

Other Candidates

Most Recent Searches

Most Famous Searches

You might also like